Stay updated with breaking news from Sunitinib Capsules. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2023. The information mentioned in this release is on the... | May 10, 2023
Hyderabad: Hyderabad-based Pharma giant Dr Reddy’s Lab on Wednesday reported a consolidated net profit of Rs 959 crore for the fourth quarter ended March 2023, up 996 percent over Rs 87.5 crore reported in the corresponding quarter in the previous year.
Shilpa Medicare fell 1.25% to Rs 424.30, extending losses for third day. The stock has declined 1.6% in three sessions from its recent closing high of Rs 431 on 10 February 2021. In the past six months, the stock has declined by 31.99% while the benchmark Sensex has added 37.61% during the same period. In a BSE filing made during market hours today, Shilpa Medicare announced the launch of Sunitinib capsules, under the brand name SUNISHIL in India. The Sunitinib capsules has been launched in three strengths of 12.5 mg, 25 mg and 50 mg Sunitinib malate is a novel oral multi targeted tyrosine ki...
The Sunitinib capsule has proven to be bioequivalent to sutent capsules of Pfizer.
Read more about Shilpa Medicare launches Sunitinib Capsules under brand name SINISHIL on Business Standard. Sunitinib malate is a novel oral multi targeted tyrosine kinase inhibitor withantitumor and antiangiogenic activities.